

CONTENTS

PART ONE: GENERAL APPROACH TO MYASTHENIA

GRAVIS. 1

1.1 Epidemiology and natural history of myasthenia gravis. 3

*Giovanni Antonini, Matteo Garibaldi, Elena Rossini, Stefania Morino,
Laura Fionda*

1.2 Pathophysiology of neuromuscular transmission 28

Maria Pia Giannoccaro, Rocco Liguori

1.3 Immunopathogenesis of myasthenia gravis 45

Valentina Damato

1.4 Clinical presentation of myasthenia gravis 67

Carmelo Rodolico, Alessia Pugliese

1.5 Therapy of myasthenia gravis before the advent of biologics. . 74

Laura Fionda, Matteo Garibaldi, Stefania Morino

PART TWO: INNOVATIVE BIOLOGICAL THERAPIES IN MYASTHENIA GRAVIS 85

2.1 B-cell depletion therapy 87

Carmen Erra, Federico Habetswallner, Bernardo De Martino, Francesco Habetswallner

2.2 The role of complement in myasthenia gravis: mechanisms and therapeutic implications. 109

Renato Mantegazza, Fiammetta Vanoli

2.3 Neonatal Fc receptor blockade 123

Francesco Saccà

2.4 Cytokine and chemokine interactions 135

Chiara Cambieri, Laura Libonati, Marco Ceccanti, Maurizio Inghilleri

PART THREE: NEW TARGETED AGENTS AND FUTURE THERAPEUTIC STRATEGIES IN MYASTHENIA GRAVIS . . 149

3 Potential future targets and strategies in the treatment of myasthenia gravis 151

Laura Fionda, Elena Rossini, Laura Tufano, Giovanni Antonini